TY - JOUR T1 - Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 1607 LP - 1613 DO - 10.21873/anticanres.15635 VL - 42 IS - 3 AU - TAKURO OKADA AU - CHIHIRO FUSHIMI AU - TAKASHI MATSUKI AU - ISAKU OKAMOTO AU - HIROKI SATO AU - TAKAHITO KONDO AU - KUNIHIKO TOKASHIKI AU - TAKUMA KISHIDA AU - TATSUYA ITO AU - GAI YAMASHITA AU - YUSUKE AIHARA AU - KENJI HANYU AU - YUKIOMI KUSHIHASHI AU - TATSUO MASUBUCHI AU - YUICHIRO TADA AU - KOUKI MIURA AU - YUKI HARADA AU - KAHO MOMIYAMA AU - TAKU YAMASHITA AU - GO OMURA AU - HIDEAKI TAKAHASHI AU - NOBUHIKO ORIDATE AU - KIYOAKI TSUKAHARA Y1 - 2022/03/01 UR - http://ar.iiarjournals.org/content/42/3/1607.abstract N2 - Background/Aim: There are no real-world comparative data of nivolumab doses of 3 mg/kg and 240 mg/body for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). We investigated the efficacy and safety of nivolumab in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) at different doses using real-world data. Patients and Methods: R/M SCCHN patients who received nivolumab were divided into the 3 mg/kg and 240 mg/body groups and retrospectively examined for efficacy and safety. Results: A total of 199 patients (3 mg/kg and 240 mg/body, 88 and 111 patients, respectively) were included. The 3 mg/kg vs. 240 mg/body groups had similar overall response rates (15% vs. 25, p=0.15), disease control rates (46% vs. 57%, p=0.15), overall survival (9.5 months vs. 10.9 months), and progression-free survival (3.7 months vs. 3.8 months, p=0.95). The incidence of immune-related adverse events was also similar in both groups. Conclusion: In R/M SCCHN patients, nivolumab showed similar efficacy and safety at doses of 3 mg/kg and 240 mg/body. ER -